ArticleOncoimmunology2024
LFA-1 regulated by IL-2/STAT5 pathway boosts antitumor function of intratumoral CD8
Article in Oncoimmunology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 10 citations in OpenAlex.
- Systems-Level Mapping of the Tumor Microenvironment Reveals Immune-Mediated Mechanisms and Potential Targets in Platinum-Resistant Ovarian Cancer.Research square · 2026Article
- Bioinformatics mining and clinical validation of CD274 as a prognostic indicator in hepatocellular carcinoma.BMC cancer · 2026Article
- Peripheral blood DNA methylation profile and immune checkpoint inhibitor response in cancer patients.ESMO open · 2026Article
- Genomic and Immune Correlates of EZH2 Expression and Activity in Olfactory Neuroblastoma.Head & neck · 2026Article
- Article
- SLAMF8 expression and prognostic significance in melanoma: A multi-omics and Mendelian randomization study.Cancer biomarkers : section A of Disease markers · 2025Article
- LFA-1/ICAM-1 Interactions Between CD8Cells · 2025Article
- Bioinformatics Analysis Reveals the Oncogenic Role and Therapeutic Potential of lncRNA SNHG25 in Colon Adenocarcinoma.International journal of genomics · 2025Article
- Potential of interleukin-7 in sepsis as a biomarker and therapeutic agent: a narrative review.Frontiers in medicine · 2025Review
- Tumor cells escape immunosurveillance by hampering LFA-1.Frontiers in immunology · 2025Review
- Regulation of anti-tumor immunity by metal ion in the tumor microenvironment.Frontiers in immunology · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Anti-PD-1 antibody therapy has achieved success in tumor treatment; however, the duration of its clinical benefits are typically short. The functional state of intratumoral CD8
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.